



PRESS RELEASE

Al improves colorectal cancer screening in Lynch syndrome

First study of Al-assisted colonoscopy for colorectal cancer surveillance in patients with genetic predisposition

Bonn, December 28 - People with Lynch syndrome have a higher hereditary risk of colon cancer. Despite regular endoscopic surveillance, it remains elevated in those affected. Researchers at the National Center for Hereditary Tumor Diseases (NZET) at Bonn University Hospital (UKB) have now found that artificial intelligence (AI) can improve the effectiveness of colonoscopy in the presence of Lynch syndrome. The study results have been published online in the United European Gastroenterology Journal.

Hereditary non-polyposis colorectal cancer (HNPCC)" - Lynch syndrome (LS) for short - is the most common hereditary colorectal cancer syndrome. Based on estimates, it is believed to affect approximately 300,000 individuals in Germany alone. LS is responsible for about two to three percent of all colon cancers. It is triggered by defects in genes responsible for repairing the human genetic material DNA. Children of those affected have a 50 percent risk of also having the pathologically altered hereditary disposition, technically known as a mutation, and thus also a high risk of developing colon cancer at a young age.

Therefore, regular monitoring by means of colonoscopy is recommended here every one to two years. "However, despite such regular endoscopic monitoring, the risk of colorectal cancer remains elevated in those affected," says Prof. Jacob Nattermann, head of the Hepatogastroenterology Section at UKB's Medical Clinic I (Director: Prof. Christian Strassburg). The researchers explain this by the fact that colonoscopy still misses a considerable number of adenomas, the potential precursors of colorectal cancer. "Small and flat adenomas in particular are at risk of being overlooked even by experienced gastroenterologists," says Prof. Nattermann.

Increase adenoma detection rate

Recent data suggest that artificial intelligence (AI)-assisted colonoscopy, also known as computer-aided detection (CADe), may help increase adenoma detection rates (ADR) in the general population. "Therefore, the aim of our study was to evaluate the diagnostic performance of AI-assisted colonoscopy in patients with Lynch syndrome," says Robert Hüneburg, senior physician at UKB's Medical Clinic I. Thus, in close collaboration with the Institute of Medical Informatics, Statistics and Epidemiology at the University of Leipzig, 46 LS patients were studied using standard endoscopy and 50 LS patients with AI-assisted colonoscopy between

Medical Director and Chairman of the Board

Tel: +49 228 287-10900 Fax: +49 228 287-9010900 wolfgang.holzgreve@ukbonn.de

Communication and media

Viola Röser Management

Tel: +49 228 287-10469 viola.roeser@ukbonn.de

Bonn University Hospital Communication and media Venusberg Campus 1 Geb. 02 53127 Bonn





December 2021 and December 2022. Here, significantly more of the Alassisted examinations (36 percent) detected adenomas than the standard examinations (26.1 percent). "This was mainly due to significantly improved detection of flat adenomas," Hüneburg says. In summary, this study was the first in the world to collect data suggesting that Al-assisted real-time colonoscopy is a promising approach to optimize endoscopic surveillance of LS patients, especially to improve detection of flat adenomas. "Due to the small sample size, based on these results, a larger multicenter study is now planned under the leadership of our department," said Prof. Nattermann.

Publication:

Hüneburg, Robert, et. al: Real-time use of artificial intelligence (CADEYE) in colorectal cancer surveillance of patients with Lynch syndrome - a randomized controlled pilot trial (CADLY) / Running title: Al assisted colonoscopy in Lynch syndrome; United European Gastroenterology Journal; https://doi.org/10.1002/ueg2.12354

Visuals:



Caption:

Study - Al-assisted colonoscopy improves surveillance of colorectal cancer in patients with Lynch syndrome: (from left) Prof. Jacob Nattermann and Dr. Robert Hüneburg in the endoscopy.

Picture credits: University Hospital Bonn (UKB) / Rolf Müller





Scientific contact:

Dr. Robert Hüneburg National Center for Hereditary Tumor Syndromes (NZET) Senior physician at the Medical Clinic I Bonn University Hospital

Tel.: +49/228/28715260

Email: Robert.Hueneburg@ukbonn.de

Press contact:

Dr. Inka Väth

Deputy Press Officer at the University Hospital Bonn (UKB) Communications and Media Office at Bonn University Hospital

Phone: +49 228 287-10596 E-mail: inka.vaeth@ukbonn.de

About the University Hospital Bonn: The UKB cares for about 500,000 patients per year, employs 8,800 people and has a balance sheet total of 1.5 billion euros. In addition to the more than 3,300 medical and dental students, a further 580 women and men are trained each year in numerous healthcare professions. The UKB is ranked first among university hospitals in NRW in the science ranking, has the third highest case mix index in Germany and was the only one of the 35 German university hospitals to increase its performance in the Corona years 2020 and 2021.